Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 2/20 | 0.68 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.68 |
| ▸ | PPARD | Q03181 | 11/20 | 0.37 |
| ▸ | PPARA | Q07869 | 5/20 | 0.37 |
| ▸ | PPARG | P37231 | 5/20 | 0.37 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.37 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | MMP2 | P08253 | 1/20 | 0.32 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7283786 | 0.83 | ITGB3 (0.73) | ITGB3ITGA2BPPARDPPARAPPARG | |
| SCHEMBL7284201 | 0.81 | ITGB3 (0.71) | ITGB3ITGA2BPPARDPPARAPPARG | |
| SCHEMBL7283166 | 0.81 | ITGB3 (0.71) | ITGB3ITGA2BPPARDPPARAPPARG | |
| SCHEMBL7273790 | 0.81 | ITGB3 (0.70) | ITGB3ITGA2BPPARDPPARAPPARG | |
| Fradafiban SCHEMBL8863359 | 0.81 | ITGB3 (1.00) | ITGB3ITGA2B | |
| Fradafiban SCHEMBL380350 | 0.81 | ITGB3 (1.00) | ITGB3ITGA2B | |
| Fradafiban SCHEMBL7280818 | 0.80 | ITGB3 (0.98) | ITGB3ITGA2B | |
| SCHEMBL7276743 | 0.78 | ITGB3 (0.76) | ITGB3ITGA2BPPARDPPARAPPARG | |
| SCHEMBL7277088 | 0.78 | ITGB3 (0.78) | ITGB3ITGA2BPPARDPPARAPPARG | |
| SCHEMBL7273484 | 0.77 | ITGB3 (0.77) | ITGB3ITGA2BPPARDPPARAPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0891774-B1 | Sustained release microcapsule for water soluble drug | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2004-06-16 | — | — | EP | disclosed |
| US-20020037837-A1 | Process for producing sustained-release preparation | TAKADA SHIGEYUKI (JP) | 2002-03-28 | — | — | US | disclosed |
| US-6287587-B2 | Forming a water in oil emulsion comprising a solution containing a water-soluble 2-piprazinone-1-acetic acid derivative and arganine as intergrin antagonist, a solvent, abiodegradable polymer, and fat and oil, removing the solvent | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-09-11 | — | — | US | disclosed |
| US-20010018075-A1 | Process for producing sustained-release preparation | SHIGEYUKI TAKADA (JP) | 2001-08-30 | — | — | US | disclosed |
| EP-0891774-A2 | Process for producing sustained release preparation | Takeda Chemical Industries, Ltd. (JP) | 1999-01-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020037837-A1 | Process for producing sustained-release preparation | LIPA, LIPE, TTPA | ITGB3 4218/4885ITGA2B 3765/4885PPARD 792/4885 |
| US-20010018075-A1 | Process for producing sustained-release preparation | LIPA, LIPE, TTPA | ITGB3 4218/4885ITGA2B 3765/4885PPARD 792/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.